Noelia Luna-Peláez

Noelia Luna-Peláez

Auto-generated profile, based on publicly available information

Noelia Luna-Peláez

Andalusian Centre for Molecular Biology and Regenerative Medicine-CABIMER, CSIC-Universidad de Sevilla-Universidad Pablo de Olavide, Seville, Spain

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 August 2015 in Scientific Reports
Verified
Journal Article
Open access
DLDunja Lukovic
Dunja Lukovic
ACAna Artero Castro
Ana Artero Castro
ADAna Belen Garcia Delgado
Ana Belen Garcia Delgado
MBMaría de Los Angeles Martín Bernal
María de Los Angeles Martín Bernal
NPNoelia Luna Pelaez
Noelia Luna Pelaez
SBShomi S. Bhattacharya
Shomi S. Bhattacharya
Retinitis pigmentosa (RP) represents a genetically heterogeneous group of retinal dystrophies affecting mainly the rod photoreceptors and in some instances also the retinal pigment epithelium (RPE) cells of the retina. Clinical symptoms and disease progression leading to moderate to severe loss of vision are well established and despite significant progress in the identification of causative genes, the disease pathology remains unclear. Lack of this understanding has so far hindered development of effective therapies. Here we report successful generation of human induced pluripotent stem cells (iPSC) from skin fibroblasts of a patient harboring a novel Ser331Cysfs*5 mutation in the MERTK gene. The patient was diagnosed with an early onset and severe form of autosomal recessive RP (arRP). Upon differentiation of these iPSC towards RPE, patient-specific RPE cells exhibited defective phagocytosis, a characteristic phenotype of MERTK deficiency observed in human patients and animal models. Thus we have created a faithful cellular model of arRP incorporating the human genetic background which will allow us to investigate in detail the disease mechanism, explore screening of a variety of therapeutic compounds/reagents and design either combined cell and gene- based therapies or independent approaches.

18 July 2019 in Cell Death & Disease
Verified
Journal Article
Open access
PDF file
NLNoelia Luna-Peláez
Noelia Luna-Peláez
RMRosana March-Díaz
Rosana March-Díaz
MCMaría Ceballos-Chávez
María Ceballos-Chávez
JGJose A. Guerrero-Martínez
Jose A. Guerrero-Martínez
Paolo GrazioliPaolo Grazioli
Paolo Grazioli
MGMario García-Domínguez
Mario García-Domínguez
Mutations in NIPBL are the major cause of Cornelia de Lange Syndrome (CdLS). NIPBL is the cohesin-loading factor and has recently been associated with the BET (bromodomains and extra-terminal (ET) domain) proteins BRD2 and BRD4. Related to this, a CdLS-like phenotype has been described associated to BRD4 mutations. Here, we show direct interaction of NIPBL with different BET members in yeast, and selective interaction with BRD4 in cells, being the ET domain involved in the interaction. To understand the relationship between NIPBL and BET proteins, we have performed RNA-Seq expression analysis following depletion of the different proteins. Results indicate that genes regulated by NIPBL largely overlap with those regulated by BRD4 but not with those regulated by BRD2. ChIP-Seq analysis indicates preferential NIPBL occupancy at promoters, and knockdown experiments show mutual stabilization of NIPBL and BRD4 on co-regulated promoters. Moreover, human fibroblasts from CdLS probands with mutations in NIPBL show reduced BRD4 at co-occupied promoters. Functional analysis in vivo, using mutants of Drosophila melanogaster, confirmed the genetic interaction between Nipped-B and fs(1)h, the orthologs of human NIPBL and BRD4, respectively. Thus, we provide evidence for NIPBL and BRD4 cooperation in transcriptional regulation, which should contribute to explain the recently observed CdLS-like phenotype associated with BRD4 mutations.

1 July 2016 in Biochimica et Biophysica Acta (BBA) - Molecular Cell Research
Verified
Journal Article
Closed access
FJFrancisco Juarez-Vicente
Francisco Juarez-Vicente
NLNoelia Luna-Pelaez
Noelia Luna-Pelaez
MGMario García-Domínguez
Mario García-Domínguez


10 May 2025 in Cell Death Discovery
Verified
Journal Article
Open access
PDF file
FGFrancisco Gallardo-Chamizo
Francisco Gallardo-Chamizo
RGRomán González-Prieto
Román González-Prieto
VJVahid Jafari
Vahid Jafari
NLNoelia Luna-Peláez
Noelia Luna-Peláez
Alfred VertegaalAlfred Vertegaal
Alfred Vertegaal
MGMario García-Domínguez
Mario García-Domínguez
Because limited oxygen and glucose supply to tissues is a serious challenge that cells must properly measure to decide between surviving or triggering cell death, organisms have developed accurate mechanisms for sensing and signaling these conditions. In recent years, signaling through posttranslational modification of proteins by covalent attachment of the Small Ubiquitin-like Modifier (SUMO) is gaining notoriety. Enhanced sumoylation in response to oxygen and glucose deprivation (OGD) constitutes a safeguard mechanism for cells and a new avenue for therapeutic intervention. However, indiscriminate global sumoylation can limit the therapeutic potential that a more precise action on selected targets would have. To clear up this, we have conducted a proteomic approach in P19 cells to identify specific SUMO targets responding to OGD and to investigate the potential that these targets and their sumoylation have in preserving cells from death. Proteins undergoing sumoylation in response to OGD are mostly related to transcription and RNA processing, and the majority of them are rapidly desumoylated when restoring oxygen and glucose (ROG), confirming the high dynamics of this modification. Since OGD is linked to brain ischemia, we have also studied cells differentiated into neurons. However, no major differences have been observed between the SUMO-proteomes of proliferating and differentiated cells. We show that the overexpression of the transcription factor SOX2 or the SUMO ligase PIAS4 has a manifest cell protective effect largely depending on their sumoylation, and that maintaining the sumoylation capacity of the coregulator NAB2 is also important to face OGD. Conversely, sumoylation of the pluripotency factor OCT4, which is sumoylated under OGD, and is a target of the SUMO protease SENP7 for desumoylation after ROG, seems to block its cell survival-promoting capacity. Thus, better outcomes in cell protection would rely on the appropriate combination of sumoylated and non-sumoylated forms of selected factors.

1 August 2018 in Stem Cell Research
Verified
Journal Article
Open access
ACAna Artero Castro
Ana Artero Castro
MLMarian León
Marian León
NLNoelia Luna-Peláez
Noelia Luna-Peláez
ABAngeles Martín Bernal
Angeles Martín Bernal
VFVerónica del Buey Furió
Verónica del Buey Furió
DLDunja Lukovic
Dunja Lukovic